AstraZeneca has licensed ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA), from Eccogene for the treatment of obesity, type 2 diabetes, and other cardiometabolic conditions
Ready to take the next step in your hormone replacement therapy treatment plan
PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) if you want to explore a dual-receptor option
Retatrutide is part of a new class of weight loss medicine referred to as triple agonists
The increase in circulating cobalamin levels is predominantly caused by enhanced production of haptocorrin.Several liver diseases like acute hepatitis, cirrhosis, hepatocellular carcinoma and metastatic liver disease can also be accompanied by an increase in circulating cobalamin
Patients taking warfarin should have INR monitoring when starting semaglutide, and the medication may delay absorption of some oral medicines due to slowed gastric emptying